Michael Smith

3 days ago | afr.com | Michael Smith |Michaël Smith

Jun 4, 2025 – 5.29pm or Subscribe to save articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe. Subscribe nowAlready a subscriber? US pharmaceutical giant Cosette has terminated its $672 million takeover bid for Adelaide-based drug company Mayne Pharma, but the target company says it will challenge the move in the courts.

4 days ago | afr.com | Michael Smith |Michaël Smith

Jun 4, 2025 – 4.34pm or Subscribe to save articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe. Subscribe nowAlready a subscriber? Australia’s medicines regulator has approved the use of a GLP-1 weight-loss drug to treat people with sleep apnoea for the first time, broadening the applications for the popular drugs beyond diabetes and heart disease.

4 days ago | afr.com | Michael Smith |Michaël Smith

Jun 4, 2025 – 12.39pm or Subscribe to save articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe. Subscribe nowAlready a subscriber? Private health insurers say the out-of-pocket cost of seeing a specialist doctor has become so expensive that many Australians are deferring critical medical care, and that this is a key reason private hospitals are struggling to fill beds.

6 days ago | afr.com | Michael Smith |Michaël Smith

Jun 2, 2025 – 2.59pm or Subscribe to save articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe. Subscribe nowAlready a subscriber? Healthscope chief executive Tino La Spina has used a private briefing with staff to rubbish health insurance giant Bupa’s chances of buying the collapsed private hospital business, and raised Brookfield Asset Management’s embarrassment at losing its investment.

1 week ago | afr.com | Michael Smith |Michaël Smith

May 30, 2025 – 2.43pm or Subscribe to save articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe. Subscribe nowAlready a subscriber? Healthscope has been in critical care for years, but it was not until earlier this year when private equity giant Brookfield Asset Management realised the prognosis on its disastrous $5.7 billion investment in Australian hospitals was terminal.